Shandong Pharmaceutical Glass Co Ltd

Shandong Pharmaceutical Glass Co Ltd

Health CareMedical Equipment and Services
  • Price (CNY)26.11
  • Today's Change0.10 / 0.38%
  • Shares traded4.76m
  • 1 Year change+2.51%
  • Beta1.0826
Data delayed at least 15 minutes, as of May 30 2023 08:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

SHANDONG PHARMACEUTICAL GLASS CO., LTD is a China-based company principally engaged in the research and development, manufacture and distribution of pharmaceutical glass products. The Company's products include molded pharmaceutical glass bottles, ampoules, phials, brown bottles, butyl rubber plugs, aluminum tops and others. The Company distributes its products in domestic and overseas markets.

  • Revenue in CNY (TTM)4.38bn
  • Net income in CNY631.60m
  • Incorporated1993
  • Employees6.41k
  • Location
    Shandong Pharmaceutical Glass Co LtdYiyuan CountyZIBO 256100ChinaCHN
  • Phone+86 5 333259028
  • Fax+86 5 333249700
  • Websitehttp://www.pharmglass.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Star Lake Bioscience Co Inc Zhqng Gngdng21.37bn705.95m9.06bn8.91k10.991.29--0.42370.49570.495717.804.222.258.5067.572,399,181.0013.525.8023.0811.9215.6719.
Zhongnongfa Seed Industry Group Co Ltd5.50bn250.19m9.31bn1.10k37.205.24--1.690.23120.23125.081.641.467.5619.604,978,035.008.923.2016.846.3810.807.836.122.511.8956.760.0930.0039.426.30533.61---11.51--
Guangdong Marubi Biotechnology Co Ltd1.83bn187.38m13.75bn1.06k73.474.20--7.530.46620.46624.558.150.46154.5626.221,722,442.004.6011.265.6314.5367.4566.569.9820.802.65--0.0995---3.105.07-29.74-11.0076.97--
Shandong Pharmaceutical Glass Co Ltd4.38bn631.60m17.26bn6.41k25.722.42--3.941.011.016.9610.740.56923.144.80683,149.808.209.1510.4711.9524.5431.2814.4115.182.46--0.093832.488.0512.434.6018.6733.5914.41
Shanghai Jahwa United Co Ltd6.97bn503.12m19.75bn5.24k38.962.61--2.830.74670.746710.2111.140.55543.026.001,330,447.004.014.765.726.4655.9259.
Data as of May 30 2023. Currency figures normalised to Shandong Pharmaceutical Glass Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

15.16%Per cent of shares held by top holders
HolderShares% Held
Bank of Communications Schroder Fund Management Co., Ltd.as of 31 Dec 202223.88m4.01%
T. Rowe Price International Ltd.as of 31 Mar 202317.27m2.90%
China Universal Asset Management Co., Ltd.as of 31 Dec 202210.51m1.77%
Capital Research & Management Co. (World Investors)as of 31 Mar 20237.99m1.34%
HuaAn Fund Management Co., Ltd.as of 31 Dec 20226.57m1.10%
Hwabao WP Fund Management Co., Ltd.as of 30 Jun 20225.73m0.96%
China Southern Asset Management Co., Ltd.as of 31 Dec 20224.96m0.83%
Harvest Fund Management Co., Ltd.as of 30 Jun 20224.70m0.79%
First Seafront Fund Management Co., Ltd.as of 31 Dec 20224.46m0.75%
Penghua Fund Management Co., Ltd.as of 30 Jun 20224.12m0.69%
More ▼
Data from 31 Dec 2022 - 31 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.